Join Optimum Strategic Communications on Thursday, 10th October 2024 for our Annual Investor Healthcare Conference.
Now in its 16th year, the conference is firmly established as a major thought leadership event in Europe, bringing together the top executives and visionaries from the healthcare industry and investment community to discuss and debate the trends set to reshape the industry far into the future.
We look forward to meeting you again this autumn, at the The Kings Fund, London.
Reviews from our past speakers on what makes Optimum's Healthcare Investor Conference unique.
Leading speakers from the healthcare and investment communities providing insights on the latest trends and impacts on the industry.
A selection of some of our brilliant panellists from previous years.
Optimum Strategic Communications
Optimum Strategic Communications is an international healthcare communications firm which specialises in strategic investor relations, corporate and financial communications. Our senior healthcare specialists, based in London, Amsterdam, Stockholm, Zurich, and New York, are experienced and trusted advisors to some of the world’s most exciting public and private companies, both large and small, across healthcare, life sciences and industrial biotechnology.
Over the last 20 years we have worked with over 300 healthcare companies, advising them on financial communications and investor relations, including major corporate activities such as fundraising, IPOs, and M&A, as well as corporate reputation and crisis scenarios.
We have an exceptional network of contacts across the international investment community in Europe and the US; contacts we have built and maintained over the last three decades. Our team includes ex-fund managers and analysts, scientists, as well as financial and corporate communications specialists.
For more information, please visit www.optimumcomms.com.
With world-renowned universities pursuing cutting-edge science, a deep pool of talent, and great infrastructure, the UK has long been a hotspot for innovation. But is it truly capitalising on its brainpower? What hurdles does it face? And can it maintain its position as a top-tier life sciences hub amidst growing competition from around the globe? A panel of industry leaders will discuss what needs to be done to ensure the UK fulfils its potential.
Chair: Dan Mahony, UK Envoy & Chair of BIA
As CEO of Novo Holdings, responsible for managing the assets and wealth of the Novo Nordisk Foundation, Kasim discusses the trends driving the Company’s investment strategy and its commitment to investing in companies that contribute to the sustainability of society and the planet.
Chair: Clive Cookson, Science Editor, The Financial Times
Professor Whitty, the UK Government’s Chief Medical Adviser and head of the public health profession, as well as a practising NHS Consultant Physician and epidemiologist, will share his insights. He will present a keynote speech, followed by a fireside chat with Optimum’s Nick Bastin, and a Q&A session.
Chair: Nick Bastin, Managing Director, Optimum Strategic Communications
Over the last few years, the pace of world class innovation has quickened, supported by a boom in private investment - yet this has not translated through to public markets. Instead, 2023 has seen weaker global public markets, where life sciences companies have struggled. Our panel of experts discuss what this means for companies looking at how to fund the next stage of their development.
Chair: Stephen Hansen, Director of BioPharma Intelligence, BioCentury
Sponsored by ICG and Cooley
We look forward to welcoming you to our conference.
The Kings Fund, London